Merck has signed a strategic collaboration agreement with Skyhawk Therapeutics to use its SkySTAR technology to develop drug candidates for patients with neurodegenerative diseases and cancer.
Merck has signed a strategic collaboration agreement with Skyhawk Therapeutics to use its SkySTAR technology to develop drug candidates for patients with neurodegenerative diseases and cancer.